Amit B. Shah - 22 Jun 2026 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Reporting relationship: CFO
Issuer ticker: OTLC
Reported as of: 22 Jun 2026
Net transaction value: +$1,000
SEC form: 4
Accepted by SEC: 22 Jun 2026, 16:30:18 UTC
Prior SEC filing: 16 Jul 2021
Next SEC filing: 14 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Amit Shah

Key filing fact

Amit B. Shah filed Form 4 for Oncotelic Therapeutics, Inc. (OTLC) on 22 Jun 2026.

Key facts

This page summarizes Amit B. Shah's Form 4 filing for Oncotelic Therapeutics, Inc. (OTLC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 16 Jul 2021.
Current net transaction value: +$1,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001719077 Primary reporting owner

Shah Amit B.

Relationship: CFO
Address: 29397 AGOURA RD SUITE 107, AGOURA HILLS
Signature: /s/ Amit Shah
Signature date: 22 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OTLC transaction

Common Stock

Purchase

Transaction value: $1,000
Shares: +20,000
Change %: +5.6%
Price: $0.0500
Shares after: 378,837
Date: 22 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On June 22, 2026, Amit Shah purchased 20,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05.